Researchers are exploring Manfredokimab AK120, a novel interleukin 17A (IL-17A) inhibitor , regarding treatment option for those diagnosed with ulcerative colitis. Initial studies indicate that this therapy https://www.targetmol.com/compound/manfidokimab